Edition:
International

Sustainable Business

Breakingviews

Breakingviews - Big Pharma’s vaccine immunity will be fleeting

Big Pharma’s vaccine victory lap may be cut short. The industry’s triumph in dispensing inoculations less than a year after the discovery of the deadly coronavirus has partially vindicated the business models of groups like Pfizer, Moderna and AstraZeneca. But as governments took on much of the risk, pharma groups’ pricing will remain a target after the pandemic.

Video

Featured Topics

More Sustainability Coverage

2019 Thomson Reuters Sustainability Report

The Pathway to Leadership for Carbon Intensive Businesses

Download now »

Interactive

Reuters Sustainability: Autos

Business model transformation and decarbonization within the autos sector

Executive Perspectives

This section combines expertise from Thomson Reuters and valued external Partners